Ronifibrate
Chemical compound
- C10AB07 (WHO)
- 3-{[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy}propyl nicotinate
- 42597-57-9
N
- 68671
- 61925
Y
- W86I18X716
- ChEMBL153983
Y
- DTXSID80195362
- Interactive image
- O=C(OCCCOC(=O)C(Oc1ccc(Cl)cc1)(C)C)c2cccnc2
InChI
- InChI=1S/C19H20ClNO5/c1-19(2,26-16-8-6-15(20)7-9-16)18(23)25-12-4-11-24-17(22)14-5-3-10-21-13-14/h3,5-10,13H,4,11-12H2,1-2H3
Y
- Key:AYJVGKWCGIYEAK-UHFFFAOYSA-N
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Ronifibrate is a fibrate, a hypolipidemic agent. It is a combined ester of clofibric acid and niacin (nicotinic acid) with 1,3-propanediol. In the body, the ester is split to 1,3-propanediol and both acids which work in the same way, lowering lipids in blood.
References
- v
- t
- e
Cholesterol absorption inhibitors, NPC1L1 | |
---|---|
Bile acid sequestrants/resins (LDL) |
Statins (HMG-CoA reductase, LDL) | |
---|---|
Niacin and derivatives (HDL and LDL) | |
MTTP inhibitors (VLDL) | |
ATP citrate lyase inhibitors (LDL) | |
Thyromimetics (VLDL) |
PPAR agonists (LDL) |
| ||||
---|---|---|---|---|---|
CETP inhibitors (HDL) | |||||
PCSK9 inhibitors (LDL) | |||||
ANGPTL3 inhibitors (LDL/HDL) |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e